<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195494</url>
  </required_header>
  <id_info>
    <org_study_id>0881A-101548</org_study_id>
    <nct_id>NCT00195494</nct_id>
  </id_info>
  <brief_title>Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis</brief_title>
  <official_title>A 24-Month,Randomized,Double-Blind,Two-Period Study to Evaluate the Efficacy and Safety of the Combination of Etanercept and Methotrexate and Methotrexate Alone in Subjects With Early Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of the combination of ETN and MTX to MTX alone on radiographic change
      and clinical disease activity in subjects with early RA over 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) &lt; 2.6.</measure>
    <time_frame>12 months</time_frame>
    <description>Effects of the combination of etanercept and methotrexate to methotrexate alone on clinical disease activity. DAS28 scale 0 - 10, 3.2 or lower showing controlled disease while 5.1 implies active disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Year 1 Participants Having an Annualized Modified Total Sharp Score (mTSS) &lt; 0.5.</measure>
    <time_frame>12 months</time_frame>
    <description>The (van der Heijde) modified total Sharp score (mTSS) is the sum of scores for erosions (range 0-280) and joint space narrowings (range 0-168) and thus has a total range of (0 - 448 ), where zero is the best score , indicating no damage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Measured by Number of Participants Reporting a Serious Adverse Event That Led to Death</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Safety report for entire trial where participants reported a serious adverse event that led to death.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">542</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etanercept + Methorexate for Period 1 (first 12 months) and Period 2 (Second 12 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etanercept + Methotrexate for Period 1 (First 12 months) and Etanercept alone for Period 2 (Second 12 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate alone in Period 1 (First 12 months) and etanercept + Methotrexate in Period 2 (Second 12 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate alone in Period 1 (First 12 months) and Methotrexate alone in Period 2 (Second 12 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 &amp; 2
Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2</description>
    <arm_group_label>1a</arm_group_label>
    <arm_group_label>1b</arm_group_label>
    <arm_group_label>2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 &amp; 2
Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Group 2b: Oral Methotrexate weekly for both Periods 1 and 2</description>
    <arm_group_label>1a</arm_group_label>
    <arm_group_label>1b</arm_group_label>
    <arm_group_label>2a</arm_group_label>
    <arm_group_label>2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2</description>
    <arm_group_label>1b</arm_group_label>
    <arm_group_label>2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Satisfies the 1987 ACR Revised Criteria for Rheumatoid Arthritis

          -  Has RA greater than or equal to 3 months and less than or equal to 2 years

        Exclusion Criteria:

          -  Received any previous treatment with MTX

          -  Received any previous treatment with ETN or other tumour necrosis factor antagonist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>March 31, 2009</results_first_submitted>
  <results_first_submitted_qc>August 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2012</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited worldwide from November 2004 to February 2006.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned equally to 1 of 4 blinded treatment groups: Group (G) 1a received the combination of etanercept (E) and methotrexate (M) in year Y1 and Y2. G1b received the combination of E and M in Y1 and E alone in Y2. G2a received M alone in Y1 and the combination of E and M in Y2. G2b received M alone in Y1 and Y2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Year 1 E+M / Year 2 E+M</title>
          <description>Following a blinded transition from year one- Etanercept injection- two injections 25 mg weekly (given at the same time at different sites)+ oral Methotrexate capsules weekly (same day as injection).
Dose consistent with the ending dose at year one (usually 20 mgs). No reduction of MTX dose is permitted in year two.</description>
        </group>
        <group group_id="P2">
          <title>Year 1 M / Year 2 E+M</title>
          <description>Following a blinded transition from year one- Etanercept two injections 25 mg weekly (given at the same time at different sites) + oral Methotrexate capsules weekly (same day as injection).
Dose consistent with the ending dose at year one (usually 20 mgs). No reduction of MTX dose is permitted in year two.</description>
        </group>
        <group group_id="P3">
          <title>Year 1 E+M / Year 2 E</title>
          <description>Following a blinded transition from year one-Etanercept two injections 25 mg weekly (given at the same time at different sites).</description>
        </group>
        <group group_id="P4">
          <title>Year 1 M / Year 2 M</title>
          <description>Following a blinded transition from year one- Methotrexate dose consistent with the ending dose of year one (usually 20 mgs).
No reduction of MTX dose is permitted in year two.</description>
        </group>
        <group group_id="P5">
          <title>Year 1 M+Placebo</title>
          <description>Oral Methotrexate capsules once weekly + two injections of placebo given at the same time at different sites.
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
        </group>
        <group group_id="P6">
          <title>Year 1 E+M</title>
          <description>Etanercept injection- two injections 25 mg weekly (given at the same time at different sites) + oral Methotrexate capsules weekly (same day as injection).
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="268"/>
                <participants group_id="P6" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="189"/>
                <participants group_id="P6" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="79"/>
                <participants group_id="P6" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>System Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed &gt;4 consecutive doses</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111">A patient with Year 1 termination had taken drug briefly during Year 2 and thus counted in the data.</participants>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="111">A patient with Year 1 termination had taken drug briefly during Year 2 and thus counted in the data.</participants>
                <participants group_id="P4" count="99"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed &gt;4 consecutive doses</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>System toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Year 1 M+Placebo</title>
          <description>Oral Methotrexate capsules once weekly + two injections of placebo given at the same time at different sites.
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
        </group>
        <group group_id="B2">
          <title>Year 1 E+M</title>
          <description>Etanercept injection- two injections 25 mg weekly (given at the same time at different sites) + oral Methotrexate capsules weekly (same day as injection).
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="268"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="542"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Year 1 Overall Number of Baseline Participants is 542</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.50" lower_limit="20.00" upper_limit="84.00"/>
                    <measurement group_id="B2" value="52.50" lower_limit="18.00" upper_limit="82.00"/>
                    <measurement group_id="B3" value="52.00" lower_limit="18.00" upper_limit="84.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Year 1 participants collected from Arms M and E+M equal the stated overall participant population of 542. 411 of those participants were then entered into Year 2 Arms E+M/E+M, M/M+E, E+M/E, M/M. This measure provides the gender population for Year 1 only in order to accurately reflect the overall baseline population of 542.</description>
          <units>Year 1 participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) &lt; 2.6.</title>
        <description>Effects of the combination of etanercept and methotrexate to methotrexate alone on clinical disease activity. DAS28 scale 0 - 10, 3.2 or lower showing controlled disease while 5.1 implies active disease.</description>
        <time_frame>12 months</time_frame>
        <population>The analysis population is the modified intent to treat participants from year 1, treatment arms M and E+M.</population>
        <group_list>
          <group group_id="O1">
            <title>Year 1 M</title>
            <description>Oral methotrexate capsules 7.5mg weekly and etanercept placebo at the same day and time.</description>
          </group>
          <group group_id="O2">
            <title>Year 1 E+M</title>
            <description>etanercept injection 50mg once weekly and oral methotrexate capsules 7.5 mg once weekly at the same time</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) &lt; 2.6.</title>
          <description>Effects of the combination of etanercept and methotrexate to methotrexate alone on clinical disease activity. DAS28 scale 0 - 10, 3.2 or lower showing controlled disease while 5.1 implies active disease.</description>
          <population>The analysis population is the modified intent to treat participants from year 1, treatment arms M and E+M.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>22.0</param_value>
            <estimate_desc>E+M (49.8%) - M (27.8%) creates the risk difference estimated value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Year 1 Participants Having an Annualized Modified Total Sharp Score (mTSS) &lt; 0.5.</title>
        <description>The (van der Heijde) modified total Sharp score (mTSS) is the sum of scores for erosions (range 0-280) and joint space narrowings (range 0-168) and thus has a total range of (0 - 448 ), where zero is the best score , indicating no damage.</description>
        <time_frame>12 months</time_frame>
        <population>The analysis population is the modified intent to treat participants from year 1, treatment arms M and E+M.</population>
        <group_list>
          <group group_id="O1">
            <title>Year 1 M</title>
            <description>Oral methotrexate capsules 7.5mg weekly and etanercept placebo at the same day and time.</description>
          </group>
          <group group_id="O2">
            <title>Year 1 E+M</title>
            <description>etanercept injection 50mg once weekly and oral methotrexate capsules 7.5 mg once weekly at the same time</description>
          </group>
        </group_list>
        <measure>
          <title>Year 1 Participants Having an Annualized Modified Total Sharp Score (mTSS) &lt; 0.5.</title>
          <description>The (van der Heijde) modified total Sharp score (mTSS) is the sum of scores for erosions (range 0-280) and joint space narrowings (range 0-168) and thus has a total range of (0 - 448 ), where zero is the best score , indicating no damage.</description>
          <population>The analysis population is the modified intent to treat participants from year 1, treatment arms M and E+M.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>21.0</param_value>
            <estimate_desc>E+M (79.7%) - M (58.7%) creates the risk difference estimated value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Measured by Number of Participants Reporting a Serious Adverse Event That Led to Death</title>
        <description>Safety report for entire trial where participants reported a serious adverse event that led to death.</description>
        <time_frame>12 and 24 months</time_frame>
        <population>The analysis population is the modified intent to treat for year 1 (542 overall baseline participants) and year 2 (411 overall baseline participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Year 2 E+M / E+M</title>
            <description>Following a blinded transition from year one- Etanercept injection- two injections 25 mg weekly (given at the same time at different sites)+ oral Methotrexate capsules weekly (same day as injection).
Dose consistent with the ending dose at year one (usually 20 mgs). No reduction of MTX dose is permitted in year two.</description>
          </group>
          <group group_id="O2">
            <title>Year 2 M / E+M</title>
            <description>Following a blinded transition from year one- Etanercept two injections 25 mg weekly (given at the same time at different sites) + oral Methotrexate capsules weekly (same day as injection).
Dose consistent with the ending dose at year one (usually 20 mgs). No reduction of MTX dose is permitted in year two.</description>
          </group>
          <group group_id="O3">
            <title>Year 2 E+M / E</title>
            <description>Following a blinded transition from year one-Etanercept two injections 25 mg weekly (given at the same time at different sites).</description>
          </group>
          <group group_id="O4">
            <title>Year 2 M / M</title>
            <description>Following a blinded transition from year one- MTX dose consistent with the ending dose of year one (usually 20 mgs).
No reduction of MTX dose is permitted in year two.</description>
          </group>
          <group group_id="O5">
            <title>Year 1 M+Placebo</title>
            <description>Oral Methotrexate capsules once weekly + two injections of placebo given at the same time at different sites.
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
          </group>
          <group group_id="O6">
            <title>Year 1 E+M</title>
            <description>Etanercept injection- two injections 25 mg weekly (given at the same time at different sites) + oral Methotrexate capsules weekly (same day as injection).
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Measured by Number of Participants Reporting a Serious Adverse Event That Led to Death</title>
          <description>Safety report for entire trial where participants reported a serious adverse event that led to death.</description>
          <population>The analysis population is the modified intent to treat for year 1 (542 overall baseline participants) and year 2 (411 overall baseline participants).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="268"/>
                <count group_id="O6" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Year 1 E+M / Year 2 E+M</title>
          <description>Following a blinded transition from year one- Etanercept injection- two injections 25 mg weekly (given at the same time at different sites)+ oral Methotrexate capsules weekly (same day as injection).
Dose consistent with the ending dose at year one (usually 20 mgs). No reduction of MTX dose is permitted in year two.</description>
        </group>
        <group group_id="E2">
          <title>Year 1 M / Year 2 E+M</title>
          <description>Following a blinded transition from year one- Etanercept two injections 25 mg weekly (given at the same time at different sites) + oral Methotrexate capsules weekly (same day as injection).
Dose consistent with the ending dose at year one (usually 20 mgs). No reduction of MTX dose is permitted in year two.</description>
        </group>
        <group group_id="E3">
          <title>Year 1 E+M / Year 2 E</title>
          <description>Following a blinded transition from year one-Etanercept two injections 25 mg weekly (given at the same time at different sites).</description>
        </group>
        <group group_id="E4">
          <title>Year 1 M / Year 2 M</title>
          <description>Following a blinded transition from year one- Methotrexate dose consistent with the ending dose of year one (usually 20 mgs).
No reduction of MTX dose is permitted in year two.</description>
        </group>
        <group group_id="E5">
          <title>Year 1 M+Placebo</title>
          <description>Oral Methotrexate capsules once weekly + two injections of placebo given at the same time at different sites.
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
        </group>
        <group group_id="E6">
          <title>Year 1 E+M</title>
          <description>Etanercept injection- two injections 25 mg weekly (given at the same time at different sites) + oral Methotrexate capsules weekly (same day as injection).
MTX dose is a forced titration from 7.5mg (3 capsules) to 20 mg weekly (8 capsules) by week 8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8"/>
                <counts group_id="E2" subjects_affected="11"/>
                <counts group_id="E3" subjects_affected="10"/>
                <counts group_id="E4" subjects_affected="12"/>
                <counts group_id="E5" subjects_affected="34"/>
                <counts group_id="E6" subjects_affected="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aterial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Atrio ventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>General gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Septic athritis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bursitis infected staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Intervetebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukamia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Malignant melanoma of sights other than skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91"/>
                <counts group_id="E2" subjects_affected="71"/>
                <counts group_id="E3" subjects_affected="89"/>
                <counts group_id="E4" subjects_affected="79"/>
                <counts group_id="E5" subjects_affected="241"/>
                <counts group_id="E6" subjects_affected="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diarhhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="67" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="44" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

